Lineage Cell Therapeutics Inc (LCTX) - Net Assets
Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) has net assets worth $20.80 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($89.64 Million) and total liabilities ($68.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Lineage Cell Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.80 Million |
| % of Total Assets | 23.2% |
| Annual Growth Rate | 8.91% |
| 5-Year Change | -19.04% |
| 10-Year Change | 0.74% |
| Growth Volatility | 92.04 |
Lineage Cell Therapeutics Inc - Net Assets Trend (1991–2024)
This chart illustrates how Lineage Cell Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore LCTX asset base for the complete picture of this company's asset base.
Annual Net Assets for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual net assets of Lineage Cell Therapeutics Inc from 1991 to 2024. For live valuation and market cap data, see how much is Lineage Cell Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $77.01 Million | +24.17% |
| 2023-12-31 | $62.02 Million | -13.78% |
| 2022-12-31 | $71.94 Million | -20.86% |
| 2021-12-31 | $90.90 Million | -4.45% |
| 2020-12-31 | $95.13 Million | -14.49% |
| 2019-12-31 | $111.25 Million | +20.60% |
| 2018-12-31 | $92.25 Million | -43.84% |
| 2017-12-31 | $164.26 Million | +25.86% |
| 2016-12-31 | $130.51 Million | +70.72% |
| 2015-12-31 | $76.45 Million | +21.88% |
| 2014-12-31 | $62.72 Million | +48.41% |
| 2013-12-31 | $42.26 Million | +73.96% |
| 2012-12-31 | $24.29 Million | -41.40% |
| 2011-12-31 | $41.46 Million | -16.12% |
| 2010-12-31 | $49.43 Million | +347.41% |
| 2009-12-31 | $11.05 Million | +354.14% |
| 2008-12-31 | $-4.35 Million | -42.69% |
| 2007-12-31 | $-3.05 Million | -63.33% |
| 2006-12-31 | $-1.87 Million | -848.83% |
| 2005-12-31 | $-196.58K | -157.02% |
| 2004-12-31 | $344.77K | +114.18% |
| 2003-12-31 | $-2.43 Million | -107.54% |
| 2002-12-31 | $-1.17 Million | -1081.85% |
| 2001-12-31 | $-99.09K | -107.52% |
| 2000-12-31 | $1.32 Million | -74.08% |
| 1999-12-31 | $5.08 Million | +111.80% |
| 1998-12-31 | $2.40 Million | -63.08% |
| 1997-12-31 | $6.50 Million | +132.14% |
| 1996-12-31 | $2.80 Million | 0.00% |
| 1995-12-31 | $2.80 Million | -12.50% |
| 1994-12-31 | $3.20 Million | -44.83% |
| 1993-12-31 | $5.80 Million | +70.59% |
| 1992-12-31 | $3.40 Million | -26.09% |
| 1991-12-31 | $4.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lineage Cell Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40246500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $484.72 Million | 618.42% |
| Other Comprehensive Income | $-2.88 Million | -3.67% |
| Total Equity | $78.38 Million | 100.00% |
Lineage Cell Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Lineage Cell Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Weifu High Tech Group
SHE:200581
|
$299.49 Million |
|
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
|
$299.49 Million |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
$299.59 Million |
|
Shandong Kehui Power Automation Co Ltd
SHG:688681
|
$299.59 Million |
|
NOCIL Limited
NSE:NOCIL
|
$299.38 Million |
|
Ihlas Haber Ajansi AS
IS:IHAAS
|
$299.36 Million |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
$299.36 Million |
|
Henan BCCY Environmental Energy Co. Ltd
SHE:300614
|
$299.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lineage Cell Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 63,419,000 to 78,381,000, a change of 14,962,000 (23.6%).
- Net loss of 18,609,000 reduced equity.
- Share repurchases of 23,000 reduced equity.
- New share issuances of 35,876,000 increased equity.
- Other comprehensive income increased equity by 192,000.
- Other factors decreased equity by 2,474,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.61 Million | -23.74% |
| Share Repurchases | $23.00K | -0.03% |
| Share Issuances | $35.88 Million | +45.77% |
| Other Comprehensive Income | $192.00K | +0.24% |
| Other Changes | $-2.47 Million | -3.16% |
| Total Change | $- | 23.59% |
Book Value vs Market Value Analysis
This analysis compares Lineage Cell Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.10x to 3.32x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1991-12-31 | $1.18 | $1.30 | x |
| 1992-12-31 | $0.65 | $1.30 | x |
| 1993-12-31 | $0.97 | $1.30 | x |
| 1994-12-31 | $0.40 | $1.30 | x |
| 1995-12-31 | $0.34 | $1.30 | x |
| 1996-12-31 | $0.34 | $1.30 | x |
| 1997-12-31 | $0.73 | $1.30 | x |
| 1998-12-31 | $0.24 | $1.30 | x |
| 1999-12-31 | $0.48 | $1.30 | x |
| 2000-12-31 | $0.12 | $1.30 | x |
| 2001-12-31 | $-0.01 | $1.30 | x |
| 2002-12-31 | $-0.09 | $1.30 | x |
| 2003-12-31 | $-0.17 | $1.30 | x |
| 2004-12-31 | $0.02 | $1.30 | x |
| 2005-12-31 | $-0.01 | $1.30 | x |
| 2006-12-31 | $-0.08 | $1.30 | x |
| 2007-12-31 | $-0.13 | $1.30 | x |
| 2008-12-31 | $-0.18 | $1.30 | x |
| 2009-12-31 | $0.24 | $1.30 | x |
| 2010-12-31 | $0.95 | $1.30 | x |
| 2011-12-31 | $0.61 | $1.30 | x |
| 2012-12-31 | $0.19 | $1.30 | x |
| 2013-12-31 | $0.27 | $1.30 | x |
| 2014-12-31 | $0.55 | $1.30 | x |
| 2015-12-31 | $0.34 | $1.30 | x |
| 2016-12-31 | $1.18 | $1.30 | x |
| 2017-12-31 | $1.42 | $1.30 | x |
| 2018-12-31 | $0.74 | $1.30 | x |
| 2019-12-31 | $0.78 | $1.30 | x |
| 2020-12-31 | $0.64 | $1.30 | x |
| 2021-12-31 | $0.56 | $1.30 | x |
| 2022-12-31 | $0.43 | $1.30 | x |
| 2023-12-31 | $0.37 | $1.30 | x |
| 2024-12-31 | $0.39 | $1.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lineage Cell Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -195.90%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.44x
- Recent ROE (-23.74%) is above the historical average (-87.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1991 | -15.22% | -700.00% | 0.02x | 1.04x | $-1.16 Million |
| 1992 | -35.29% | -1200.00% | 0.03x | 1.03x | $-1.54 Million |
| 1993 | -25.86% | -1500.00% | 0.02x | 1.02x | $-2.08 Million |
| 1994 | -75.00% | -2400.00% | 0.03x | 1.13x | $-2.72 Million |
| 1995 | -71.43% | -2000.00% | 0.03x | 1.07x | $-2.28 Million |
| 1996 | -71.43% | -2000.00% | 0.03x | 1.07x | $-2.28 Million |
| 1997 | -46.15% | -3000.00% | 0.01x | 1.28x | $-3.65 Million |
| 1998 | -87.50% | -700.00% | 0.11x | 1.17x | $-2.34 Million |
| 1999 | -107.81% | -528.18% | 0.18x | 1.12x | $-5.99 Million |
| 2000 | -373.75% | -9382.43% | 0.03x | 1.27x | $-5.06 Million |
| 2001 | 0.00% | -2408.44% | 0.08x | 0.00x | $-3.65 Million |
| 2002 | 0.00% | -735.09% | 0.26x | 0.00x | $-2.73 Million |
| 2003 | 0.00% | -313.09% | 0.52x | 0.00x | $-1.50 Million |
| 2004 | -894.89% | -448.20% | 0.45x | 4.41x | $-3.12 Million |
| 2005 | 0.00% | -229.66% | 0.46x | 0.00x | $-2.05 Million |
| 2006 | 0.00% | -160.46% | 1.79x | 0.00x | $-1.68 Million |
| 2007 | 0.00% | -137.48% | 5.97x | 0.00x | $-1.13 Million |
| 2008 | 0.00% | -251.42% | 1.45x | 0.00x | $-3.35 Million |
| 2009 | -73.00% | -267.19% | 0.14x | 1.91x | $-5.85 Million |
| 2010 | -29.30% | -303.91% | 0.07x | 1.40x | $-15.00 Million |
| 2011 | -57.65% | -379.25% | 0.10x | 1.60x | $-19.38 Million |
| 2012 | -223.54% | -1265.64% | 0.06x | 3.10x | $-22.38 Million |
| 2013 | -296.49% | -1533.82% | 0.05x | 3.90x | $-45.36 Million |
| 2014 | -99.88% | -1870.75% | 0.03x | 2.05x | $-40.06 Million |
| 2015 | -174.75% | -1854.42% | 0.03x | 3.52x | $-49.68 Million |
| 2016 | 28.47% | 1490.76% | 0.02x | 1.21x | $21.78 Million |
| 2017 | -12.28% | -1114.73% | 0.01x | 1.07x | $-36.24 Million |
| 2018 | -49.01% | -3247.88% | 0.01x | 1.08x | $-55.37 Million |
| 2019 | -10.37% | -792.22% | 0.01x | 1.11x | $-23.00 Million |
| 2020 | -21.46% | -2671.28% | 0.01x | 1.12x | $-30.27 Million |
| 2021 | -46.65% | -1104.18% | 0.02x | 1.89x | $-52.24 Million |
| 2022 | -35.82% | -178.69% | 0.12x | 1.69x | $-33.61 Million |
| 2023 | -33.88% | -240.20% | 0.09x | 1.59x | $-27.83 Million |
| 2024 | -23.74% | -195.90% | 0.08x | 1.44x | $-26.45 Million |
Industry Comparison
This section compares Lineage Cell Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,871,658
- Average return on equity (ROE) among peers: -26.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lineage Cell Therapeutics Inc (LCTX) | $20.80 Million | -15.22% | 3.31x | $299.43 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $200.23 Million | -28.52% | 0.14x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-5.75 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $52.99 Million | -121.23% | 0.22x | $3.61 Billion |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more